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Abstract 
Background: Dengue fever (DF) remains the most rapidly spreading mosquito-borne viral disease 
worldwide, and in recent decades a re-emergence of the virus and its severe forms has been observed. DF 
can present in a wide spectrum of manifestations ranging from self-limited DF, to severe forms such as 
dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Certain elements of the lipid profile 
may aid early prognostication in patients at risk for severe types of dengue. The primary goal of this 
literature review is to address whether lipid profile changes can be utilized to predict development of 
dengue fever severity in pediatric patients. 
Methods: An exhaustive search of available literature was conducted using MEDLINE-Ovid, Web of 
Science, CINAHL, and Google Scholar using the keywords: lipoprotein, lipid profile, and dengue fever. 
Studies were included if the primary data evaluated lipid profile changes in the pediatric population and 
their correlation with severe outcomes of DF. Bibliographies were also searched for relevant studies. 
Articles were excluded if studies were conducted on adult patients. Relevant articles were assessed for 
quality using the GRADE. 
Results: Three studies fit the inclusion criteria and were included in this systematic review. All studies 
were observational prospective studies looking at the relationship between lipid profile alterations with 
severe forms of dengue infection. Decreases in total cholesterol (TC) and LDL levels were statistically 
significant. Other lipid profile components, such as HDL, VLDL and triglycerides, did not have a significant 
change with increasing dengue severity. 
Conclusion: Studies demonstrated that specific changes in the lipid profile can anticipate development of 
severe forms of dengue fever in pediatric patients. Total cholesterol and LDL measurements were 
consistently lower in association with DHF and DSS. However, TC and LDL’s sole use as prognostic 
biomarkers for increased dengue severity is premature and inconclusive. While a great starting point for 
more research, more studies involving time-ordered analysis and uniform measurements are needed to 
effectively and accurately predict progression to severe forms of dengue. 
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Abstract  
Background: Dengue fever (DF) remains the most rapidly spreading mosquito-borne viral 
disease worldwide, and in recent decades a re-emergence of the virus and its severe forms has 
been observed. DF can present in a wide spectrum of manifestations ranging from self-limited 
DF, to severe forms such as dengue hemorrhagic fever (DHF) and dengue shock syndrome 
(DSS). Certain elements of the lipid profile may aid early prognostication in patients at risk for 
severe types of dengue. The primary goal of this literature review is to address whether lipid 
profile changes can be utilized to predict development of dengue fever severity in pediatric 
patients. 
Methods:  An exhaustive search of available literature was conducted using MEDLINE-Ovid, 
Web of Science, CINAHL, and Google Scholar using the keywords: lipoprotein, lipid profile, 
and dengue fever. Studies were included if the primary data evaluated lipid profile changes in the 
pediatric population and their correlation with severe outcomes of DF. Bibliographies were also 
searched for relevant studies. Articles were excluded if studies were conducted on adult patients. 
Relevant articles were assessed for quality using the GRADE. 
Results: Three studies fit the inclusion criteria and were included in this systematic review. All 
studies were observational prospective studies looking at the relationship between lipid profile 
alterations with severe forms of dengue infection. Decreases in total cholesterol (TC) and LDL 
levels were statistically significant. Other lipid profile components, such as HDL, VLDL and 
triglycerides, did not have a significant change with increasing dengue severity.  
Conclusion: Studies demonstrated that specific changes in the lipid profile can anticipate 
development of severe forms of dengue fever in pediatric patients. Total cholesterol and LDL 
measurements were consistently lower in association with DHF and DSS. However, TC and 
LDL’s sole use as prognostic biomarkers for increased dengue severity is premature and 
inconclusive. While a great starting point for more research, more studies involving time-ordered 
analysis and uniform measurements are needed to effectively and accurately predict progression 
to severe forms of dengue.  
Keywords: Dengue fever, lipid profile, lipoprotein, pediatric 
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Lipid Profile Changes as a Potential Prognostic Marker for the 
Prediction of Dengue Fever Severity in Pediatric Patients 
BACKGROUND 
Dengue fever (DF) remains the most rapidly spreading mosquito-borne viral disease 
worldwide,1 and in recent decades a re-emergence of the virus and its severe forms has been 
observed. Found in the tropical and sub-tropical regions of the world, over 2.5 billion people live 
in dengue endemic countries, with approximately 50 million dengue infections diagnosed 
annually.2 Of those diagnosed, an estimated 500 000 people, the majority being children, develop 
severe forms of dengue and require hospitalization annually. About 2.5% of those affected do not 
survive.1 In recent years, increases in incidence have partly been attributed to urbanization and 
air travel,3 and infections are only expected to rise. 
There are 4 serotypes of the dengue Flavivirus that can present in a wide spectrum of 
manifestations. Presentations range from self-limited DF, causing arthralgia, myalgia, and 
headache, to the more severe forms, such as dengue hemorrhagic fever (DHF), presenting with 
thrombocytopenia, hemorrhagic manifestations and increased vascular permeability, and dengue 
shock syndrome (DSS), which can be fatal if left untreated.3,4 The World Health Organization 
(WHO) developed criteria in 1997 and 2009 for dengue fever severity classification.2,5 See 
Figure 1 and 2.  
Treatment for DF has always been supportive, while severe forms of the disease require 
critical medical management of the patient’s body fluid volume.1 The ability to make early 
predictions of severe dengue in patients who display no warning signs and are at risk of 
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developing severe DHF and DSS is critical in choosing appropriate intensive supportive therapy 
and improving survival since the newly developed vaccine is not widely accessible.3 
Early detection of individuals at risk of developing severe forms of dengue could be 
possible with the identification of an ideal biomarker, which has been the focus of several 
research studies. While the mechanism behind individuals who contract DF and progress to 
severe dengue remains unclear; research speculates that the host immune response is a 
significant factor in dengue pathogenesis and suggest severe forms are most likely associated 
with immunopathology.3 This has led to the examination of immune response components, 
endothelial activation markers, and other biochemical and genetic markers as potential 
biomarkers.3,6 
        It has been established that hypolipidemia occurs in critically ill patients and is an 
independent predictor of clinical outcomes.7,8 Theories postulate that the immunopathogenesis of 
dengue infections demonstrate the possibility of lipoprotein’s ability to modify inflammatory 
immune function and host immune response during infections.9 Research also suggests that 
during viral infections, lipoproteins bind to viruses and neutralize their negative effects, while 
certain viruses use LDL receptors for entrance into cells.10 Similarly, HDL and LDL have been 
shown to modulate hepatitis C virus infectivity, promoting virus-cell interaction by facilitating 
virus-cell entry.11-15 Research also demonstrated that using markers to indicate thrombocytopenia 
and hemorrhagic manifestations have been associated with severe forms of dengue.10 Despite 
several studies looking at possible biomarkers to indicate severe forms of dengue, there have 
been few studies that address and elucidate a correlation between dengue fever severity and 
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changes in the lipid profile. Can lipid profile changes predict dengue fever severity in the 
pediatric patient? 
METHODS 
An exhaustive search of available literature was conducted using MEDLINE-Ovid, Web 
of Science, CINAHL, and Google Scholar using the keywords: lipoprotein, lipid profile, and 
dengue fever. Bibliographies were also searched for other relevant studies. Studies were included 
if the primary data evaluated lipid profile changes in the pediatric population and their 
correlation with severe outcomes of dengue fever. Further search refinement included data 
collected using human trials only and articles published in the English language. Articles were 
excluded if studies were conducted on adult patients. Relevant articles were assessed for quality 
using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE).16 
According to the National Institute of Health (NIH) clinical trials inquiry, there are no current 
trials in any phase examining the lipid profile or its components as a prognostic biomarker in 
patients with dengue fever. 
 
RESULTS 
The initial search yielded 48 articles for review. Following elimination of duplicates and 
screening of relevant articles for primary data and human studies published in English, a total of 
three articles17,18,19 met eligibility criteria. All articles selected were prospective observational 
studies. See Table 1. Another prospective observational study was considered, but fell under 
exclusion criteria because it evaluated adults.10 
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Biswas et al 
  
 Biswas et al17 conducted a prospective study between 2005-2013 to understand the 
correlation between cholesterol levels during a dengue infection, understand how cholesterol 
levels change over time among patients with severe forms of dengue, and to assess the 
relationship of cholesterol level at presentation with development of severe dengue. The study 
was conducted at the Infectious Disease Ward of the Hospital Infantil Manuel de Jesus Rivera in 
Managua, Nicaragua, which is the National Pediatric Reference Hospital that manages the vast 
majority of children in need of tertiary care across the country.17 
         Eligibility criteria included infants and children between the ages of 6 months and 14 
years old presenting with a fever or history of fever for less than 7 days and one or more of the 
following signs and symptoms: headache, arthralgias, myalgias, retro-orbital pain, positive 
tourniquet test, petechiae, or signs of bleeding. Annually, both inpatients and outpatients were 
enrolled during the peak of dengue season (August 1 to January 31) and were followed clinically 
through the acute phase of illness. For each enrolled participant, a medical history and complete 
physical exam was performed. Vital signs, signs and symptoms, and fluid balance and treatment 
were documented 2 times a day, and a blood sample was drawn daily for 3 days to include: 
complete blood counts, platelets, blood chemistry, and serological, virological, and molecular 
biological tests for dengue infection. Additionally, a convalescent serum sample (14-21 days 
post-onset of illness) was drawn for paired serological testing. Information was collected every 
12 hours for inpatients and every 24 hours for outpatients who were asked to return daily. For 
inpatients, a non-fasting blood sample was taken each morning to measure serum lipids, while 
non-fasting blood sample was obtained at each follow-up visit for outpatients. A case was 
considered laboratory-confirmed dengue when acute infection was demonstrated by: detection of 
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DENV RNA by RT-PCR; isolation of DENV; seroconversion of DENV-specific IgM antibodies 
observed by MAC-ELISA in paired acute and convalescent phase samples; and/or a > 4-fold 
increase in anti-DENV antibody titer measured using Inhibition ELISA in paired acute and 
convalescent phase samples. Patients who tested negative for DENV infection were classified as 
patients with other febrile illness (OFI).  The laboratory-confirmed cases were classified by 
severity using 1997 and 2009 WHO classification criteria (See Figure 1 and 2), and 3 
standardized clinical intervention levels that were established in the DENCO study sponsored by 
the WHO. To evaluate the effect of cholesterol at presentation on risk of development of severe 
dengue, relative risks and 95% confidence intervals were calculated using multi-variable 
modified Poisson models. 
         Following exclusions, 1236 patients were suitable for analysis, including 789 (64%) 
laboratory-confirmed as DENV positive and 447 (36%) tested negative and classified as OFI. 
From the participants, it was observed that children aged 9 to 12 were more likely to be classified 
as having more severe forms of dengue, most patients (82%) were hospitalized and patients 
generally presented on day 4-5 of illness. As the first study to analyze changes in cholesterol 
levels by day of illness in dengue patients, with use of time-ordered analysis, it was found that 
total serum cholesterol (TC), was significantly lower in dengue-positive patients than in dengue-
negative patients on day 3-8 of illness (p<0.05), which is illustrated in Figure 3. Trajectories for 
LDL levels were similar to those of TC on day 2 (p<0.05) and days 4-8 of illness (p<0.001). In 
contrast, HDL levels were significantly decreased only on days 5-7 of illness (p<0.001). 
Moreover, results showed that LDL levels had the greatest decrease, which suggests its effect on 
lowering total cholesterol. When examining the trajectories of cholesterol by severity during the 
course of illness regardless of severity classification, TC was significantly lower in patients who 
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developed severe dengue compared to patients with mild dengue on days 5-7 of illness using the 
WHO 1997 classification (p<0.001), on days 4-8 of illness using the WHO 2009 classification 
(p<0.05), and on days 5-8 of illness using standardized intervention categories (p<0.05). See 
Figure 4. Finally, using the WHO 1997 disease severity classification showed that for each 10 
mg/dl decrease in TC and LDL-C at presentation, the risk of development of DHF/DSS 
increased by 9% (95% CI: 0-19%) and 12% (95% CI: 0-26%), respectively, suggesting its 
potential use as a prognostic marker for severe forms of the disease.17 See Table 2. 
 
Suvarna and Rane 
         During a 2006 dengue outbreak in Mumbai, India, this prospective study18 was conducted 
over 18 months at a tertiary care hospital on dengue patients to determine the relationship 
between lipoproteins and dengue severity, as well as other outcomes, such as patient survival, 
bleeding severity, capillary leakage, supportive therapy requirement, and duration of hospital 
stay.18  
         Included in this study were 50 children (1 month to 18 years old) with dengue fever (DF) 
and 50 age- and sex-matched non-febrile children, considered controls. After participants were 
classified and diagnosed using standard WHO criteria, 18 (36%) patients were DF, 19 (38%) 
were DHF and 13 (26%) were DSS. Age distribution demonstrated that severe dengue was more 
frequent in the 0 to 3-year age group vs. the 12 to 18-year age group.  The opposite was shown 
for mild dengue (DF), where it was more common at age 12-18 years than at 0-3 years. The 
study compared lipid profile of dengue cases and controls, between lipid profile in survived and 
expired patients and between lipid profile and disease severity. Excluded from this study were 
cases or controls with nephrotic syndrome, obesity (BMI ≥30), or parental history of diabetes 
mellitus, obesity, lipid disorder, or coronary artery diseases at age < 55.18 
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         When comparing lipid profile of cases and controls, mean triglycerides (TG) and VLDL 
levels were higher in cases than controls (P value < 0.05), while mean HDL and LDL levels were 
lower in cases than in controls (P values = 0 and 0.001, respectively). The study also showed that 
mean cholesterol level was lower in DSS than in controls (P = 0.005), but not in those with DHF 
and DF (P values 0.724 and 0.108, respectively). Cholesterol and VLDL were different among 
the disease severity groups, whereas TG, HDL and LDL did not differ. Lower levels were seen 
in DSS and higher levels in DF. Data showed that mean cholesterol level was higher in DF than 
in DHF, DSS (P-value 0.01, 0.001, respectively) but did not differ between DHF and DSS. The 
study also demonstrated that the odds of having DSS are four times more with a TG <150, than 
at a TG>150. Otherwise, none of the lipids significantly predicted survival or death.18 
  
Van Gorp et al 
  
         This prospective study19 focused on significant changes in lipid profile in patients with 
DHF, and whether these changes are relevant to clinical outcomes.   
         With yearly outbreaks of dengue fever, the study was conducted at the Dr. Kariadi 
University Hospital of the University of Diponegoro in Semarang, Central Java, Indonesia. From 
July-October 1996, enrolled in the study were 50 consecutive children (mean age +/- SD, 6.5 +/-
2.8 years) clinically diagnosed using WHO criteria with severe DHF (DHF grade III and IV) 
who were admitted to the pediatric intensive care unit, 20 age-related patients with mild DHF 
(DHF grade I and II) admitted to the pediatric ward and 20 age-related, non-febrile healthy 
children. Clinical diagnosis of DHF grade I-IV was determined by 1997 WHO criteria.4 For all 
participants, blood samples for analysis of serum lipid profile (TC, HDL, LDL, and triglyceride) 
and cytokines were collected on day of admission. Dengue virus infection was objectively 
confirmed using serologic assays. Additionally, blood samples were taken for culture to exclude 
 - 14 -  
bacterial infections. In follow-up, 13 patients (26%) with DHF III and IV did not survive due to 
shock or bleeding complications.19 
         Results demonstrated significant difference in serum cholesterol, HDL and LDL levels 
when comparing patients with mild DHF, severe DHF, and healthy control subjects, as well as 
with the patients who did not survive. The lowest levels of TC, HDL and LDL were shown in 
patients with severest disease, and in the sub-analysis of patients with severe DHF who survived 
and who did not survive, the lowest lipid levels were seen in the non-survivor group. In contrast, 
triglyceride levels were the opposite. The highest levels were seen in patients with the most 
severe cases, but values were not significantly different among the 3 groups. Similarly, the 
highest triglyceride levels were shown in the patients who died.19 See Figure 5. 
         Findings from this study suggest that demonstrated alterations in the lipid profile could 
be used as prognostic markers to predict clinical outcome in dengue infected patients. The 
authors also consider these differences to represent surrogate markers for severe infection as they 
could denote actual markers for risk for severe infection leading to negative clinical outcomes. 
From prior studies, researchers believe these results are due to the link between lipid metabolism 
and cytokine production. The authors recommend further, prospective, follow up to determine if 
these measurements can be used in clinical practice.19  
DISCUSSION 
With the advent of climate change, continued globalization, and viral evolution, dengue 
infections along with other mosquito-borne illnesses are expected to rise. The recent emergence 
and global impact of the Zika virus has underlined the need for additional studies and research to 
improve mosquito-borne disease detection and effective treatment. Determining the relationship 
between DF and specific biomarkers could potentially pave the way for earlier detection and 
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thus, improved outcomes for other mosquito borne illnesses as well.  Rising numbers of dengue 
infections has made it critical to determine a reliable prognostic marker to predict dengue 
severity and ensure timely and proper therapeutics.20  
This review aimed on evaluating whether changes in the lipid profile can predict 
development of severe forms of dengue. Although evidence is variable and limited, results of the 
studies presented suggest that alterations of certain components of the lipid profile may play a 
vital role in predicting the development of more severe forms of DF. In all studies 
reviewed,17,18,19 results showed decreasing serum cholesterol levels correlated with increasing 
dengue severity, suggesting the utility of the lipid profile as a surrogate biomarker and indicator 
of a poor clinical outcome. 
In addition to observing lower levels of total cholesterol with severe forms of DF, 
studies17,19 also saw decreases in LDL with increasing dengue severity. In Biswas et al,17 greater 
decreases in LDL were evident in DHF and DSS compared to mild dengue, which was theorized 
to drive the reduction in total cholesterol. Duran et al10 explains this as a result of LDL’s ability 
to facilitate entry of the dengue virus into the cell via its receptors. Moreover, this study10 noted a 
positive correlation between lipid values and platelet count. Lower LDL values in severe dengue 
were linked with low platelet counts, which aligns with hemorrhagic status in severe forms of 
dengue. The study by Suvarna and Rane18 also found LDL levels associated with an increased 
likelihood of DHF, but statistical tests were not significant between lower TC and severe dengue. 
Other components of the lipid profile were inconclusive as the studies reviewed 
demonstrated inconsistent results. Shown in Figure 5, the van Gorp et al study19 found a 
significant decrease in total cholesterol, LDL and HDL among patients with severe DHF in 
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comparison to those classified with mild DF or healthy subjects, suggesting their use as 
prognostic markers to predict clinical outcome. In contrast, both studies17,18 determined that HDL 
results were not statistically significant. Similarly, while VLDL was looked at in two studies,18,19 
its role was not conclusively defined, warranting future studies in the pathogenesis of the viral 
infection and its underlying mechanism. 
Additionally, the study conducted by Biswas et al17 solely accounts for time ordered 
analysis of cholesterol levels in relation to dengue severity outcome, highlighting the need for 
more time ordering studies. This way, results will determine whether cholesterol levels affect 
development of severe dengue or if it is a result of developing severe dengue. Anticipation and 
early recognition of DHF and DSS will not only guide therapy, but prompt timely and 
appropriate medical management to improve patient outcomes.   
         Despite these findings, significant limitations should be addressed regarding small 
sample size, variability in the use of appropriate group comparisons, inability to generalize 
evidence to general population, use of PCR in diagnosing dengue objectively, failure to evaluate 
the lipid profile in its entirety, and measuring lipoproteins over time. Two studies17,18 were of 
small sample size, likely causing imprecision in results. In comparison to Biswas et al,17 which 
analyzed 1236 who fit inclusion criteria over the course of 9 years, sample size and study period 
were considerably small. Suvarna and Rane18 studied 100 subjects total over an 18-month period, 
while van Gorp et al19 evaluated 90 subjects over four months.  
Another weakness involved the variability across studies. An important variable to 
account for is the differences or non-specifications in control groups or lack of control groups. 
Two studies17,18 provided control groups defined as non-febrile or healthy controls. Comparing 
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these studies, age distribution was not specified in one study17, but summarized as “age-related”, 
which is potentially an important flaw considering that the burden of disease and severe dengue 
was found predominantly in infants aged 4-9 months and in children 5-9 years old.4 Providing an 
age distribution would have accentuated the results, identifying what pediatric population was 
more at risk of developing severe dengue. Additionally, one study17 did not provide a control 
group defined as healthy subjects, but instead classified a study group as OFI or not having DF. 
Nonetheless, results from these prospective studies are consistent in demonstrating that total 
cholesterol and LDL were consistently higher in controls and OFI, and lower in severer forms of 
dengue.   
However, the importance of including healthy controls is further emphasized by the fact 
that lipid profiles are non-specific and can also change in patients with severe infections or 
illness. The Wilson et al 2005 study20 demonstrated low cholesterol levels in sepsis or critically 
ill or injured patients, and is consistent with a study7 identifying hypolipidemia as an 
independent predictor of clinical outcome in critically ill patients.  Generalizing the results of the 
reviewed studies17,18,19 is limited by the lack of specificity of using lipid profiles for prognosis in 
any patient with fever, but altering lipoprotein levels are useful in patients presenting where 
dengue fever is suspected. 
Limitations were observed in the methods sections regarding clinically and objectively 
diagnosing DF and severity. Across studies, either or both 1997 or 2009 WHO criteria were used 
to clinically diagnose dengue severity, while various methods were used to objectively diagnose 
DF in study subjects. Two studies17,19 utilized dengue PCR for diagnosis, but due to financial and 
infrastructure constraints, the Denguecheck-WB test was performed for diagnosis in the Suvarna 
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and Rane study.18 The Denguecheck-WB test, which studies have shown to have high specificity 
but low sensitivity, and poor predictive capacity to differentiate between primary and secondary 
dengue infections.18 
Another evident variability between studies are the lipid profile components. Only one 
study18 examined the entire lipid profile, including TC, HDL, LDL VLDL and triglycerides, 
against changes in dengue severity, which affects accurate comparisons. Specifically, in Biswas 
et al,17 the LDL was not measured for the first two years of study, which affected measurements 
for analysis, while triglycerides were not measured at all. Consistently looking at the entire lipid 
profile would facilitate researchers in determining which components are negatively or positively 
correlated with dengue severity. While LDL has been emphasized as a probable determinant of 
severe dengue outcome, ascertaining consistent trends in lipid components would help 
researchers understand whether LDL alone was driving reduction in total cholesterol, or if other 
components are contributing. This would make the evidence more promising.  
 Finally, a limitation can also be considered in examining changes in cholesterol levels 
throughout the course of dengue infection. While Biswas et al17 study design did account for 
time-ordering analyses, which ensured exposure of the virus preceding the outcome, obtaining 
baseline lipid profile values or convalescent measurements from subjects would have been 
interesting and informative for researchers. This finding may suggest whether high cholesterol 
and lipoproteins have protective and beneficial effects on the immune system in the 
immunopathogenesis of dengue fever. Interestingly in a study by Iribarren et al,21 it was 
observed that individuals with low cholesterol at the start of the study endured more hospital 
admissions for infectious diseases in the next 15 years.  
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Despite this review demonstrating an apparent correlation between dengue severity and 
lipid profile, the evidence is of very low quality based on the current research available. 
Currently, the use of the lipid profile as a surrogate biomarker to predict dengue severity is non-
specific, thus underlining the need for further research to validate its role in a clinical setting. To 
be utilized as an actual biomarker, there is a definite need for more time-ordered studies that will 
help clarify if lipid profile, or certain components of the lipid profile impact development of 
severe dengue or if it is a result of developing severe dengue. Regardless, elucidating these 
findings for clinical practice would be vital. 
CONCLUSION 
In conclusion, these studies demonstrate that specific changes in the lipid profile can 
anticipate development of severe forms of dengue fever in pediatric patients. Total cholesterol 
(TC) and LDL measurements were consistently lower in association with DHF and DSS. 
However, TC’s and LDL’s sole use as prognostic biomarkers for increased dengue severity is 
premature and inconclusive. These studies are a great starting point for more research, but 
additional studies involving time-ordered analysis and uniform measurements are needed to 
effectively and accurately predict progression to severe forms of dengue. Furthermore, the ability 
to explore and identify trends in all aspects of the lipid profile, as well as other routine laboratory 
markers, have potential in creating a prognostic biomarker panel to identify risk of developing 
severe forms of dengue fever in susceptible populations. With the effects of climate change, 
globalization and viral evolution, it is in the interest of global medicine that future research 
discern at risk groups for severe infections and reliable prognostic markers not only for dengue 
fever, but for its fellow mosquito-borne illnesses, such as chikungunya, Japanese encephalitis 
and Zika virus, that are of concern for widespread outbreak.  
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Table 1: Quality Assessment of Reviewed Articles 
Study 
  
Design Downgrade Criteria Quality 
Limitations Indirectness Inconsistency Imprecision Publication 
bias 
Biswas 
et al16 
Prospective 
Observational 
Seriousa Not serious Not serious Not serious No bias 
likely 
Very 
low 
Suvarna 
and 
Rane17 
  
Prospective 
Observational 
  
Seriousb Not serious Not serious Serious c Likely d Very 
low 
VanGorp 
et al18 
Prospective 
Observational 
Not serious Not serious  Not serious Serious e No bias 
likely 
Very 
low 
a 
LDL-C not measured in first two of nine years and triglycerides were not measured 
b 
Due to financial and infrastructure constraints, dengue PCR was not performed for diagnosis, instead the Dengucheck-WB 
test was performed. 
c
 The sample size is small n=100 
d
 The high disease severity in this cohort due to KEM Hospital being the premier tertiary care centres with referrals from all 
over the state of Maharashtra, India 
e 
The sample size is small n=90 
Table 2. Effect of cholesterol level at presentation on development of severe dengue 
outcome using the WHO 1997 disease severity classification16 
 
 Cholesterol type 
Variable Total serum 
cholesterol RR 
(95%CI) 
LDL-C RR (95%CI) 
 
HDL-C RR (95%CI) 
Cholesterol per-10 
mg/dl) 
1.09 (1.00-1.19) 1.12 (1.00-1.26) 1.18 (0.98-1.42) 
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Figure 1-  WHO guidelines (1997) for the treatment of dengue fever/dengue 
hemorrhagic fever5 
 
 
 
 
 
Figure 2:  WHO guidelines (2009) Dengue, guidelines for diagnosis, treatment, 
prevention and control.2 
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FIGURE 3: Age- and gender-adjusted marginal mean cholesterol levels (mg/dl) 
by DENV infection status and day of illness; 3A. Trajectories of cholesterol levels 
by DENV infection status; 3B. Trajectories of LDL-C and HDL-C levels by 
DENV infection status. The day of fever onset was defined as day 1 of illness.  
 
Abbreviations: 
DENV: Dengue virus 
LDL-C: Low-density lipoprotein cholesterol 
HDL-C: High-density lipoprotein cholesterol 
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FIGURE 4: Age- and gender-adjusted marginal mean cholesterol levels (mg/dl) 
by dengue severity classification and day of illness; 4A, 4B, 4C. Trajectory of total 
serum cholesterol by dengue severity using the WHO 1997 classification, WHO 
2009 classification, and IC, respectively. 4D, 4E, 4F. Trajectory of LDL-C and 
HDL-C by dengue severity using the WHO 1997 classification, WHO 2009 
classification, and IC, respectively. 
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Abbreviations: 
DF: Dengue fever 
DHF: Dengue hemorrhagic fever 
DSS: Dengue shock syndrome 
DWS: Dengue with or without warning signs 
SD: Severe dengue 
IC: Standardized intervention categories 
 
IC 1/IC 2: Mild dengue 
IC 3: Severe dengue 
LDL-C: Low-density lipoprotein cholesterol 
HDL-C: High-density lipoprotein cholesterol 
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Figure 5: Comparing lipid profile levels in control subjects and patients with 
DHF and DSS on day of admission to hospital.18 
 
Abbreviations: 
TC: Total cholesterol 
HDL: High density lipoprotein 
LDL: Low density lipoprotein 
TG: Triglyceride 
Mild DHF: Mild dengue hemorrhagic fever 
DSS: Dengue shock syndrome  
 
TC HDL LDL TG
Control 3.45 1.25 1.79 0.83
Mild DHF 3.1 0.72 1.77 1.69
DSS 2.35 0.21 1.04 2.17
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